KESIMPTA®▼ (ofatumumab)
Open configuration optionsOpen configuration options
KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.
Efficacy profile you can trust
KESIMPTA is the only subcut B-cell therapy with an established long-term (up to 6 year) efficacy and safety profile in RRMS
9 out of 10 KESIMPTA patients achieved no evidence of disease activity (NEDA-3) at Year 6*3
KESIMPTA met the primary endpoint in ASCLEPIOS I/II, with up to 58% reduction in ARR vs teriflunomide (ASCLEPIOS I: 51% [0.11 vs 0.22]; HR: 0.49, ASCLEPIOS II: 58% [0.10 vs 0.25]; HR: 0.42; both p<0.001).4
KESIMPTA demonstrated a generally well-tolerated safety profile, with preserved mean IgG levels for up to 6 years1–4
IgG levels are based on a post-hoc analysis study.4
KESIMPTA enables patients to self-administer at home or on the go in just 1 minute a month after an initial dosing period†1,2
This flexibility to self-administer without the need for HCP involvement means dosing can occur at home or elsewhere appropriate outside the hospital setting. The first injection should be performed under the guidance of a healthcare professional.